July 17, 2020: NeuroGT obtained the Exclusive License Agreement From (UNC-CH), to develop the gene therapy product

July 17, 2020: NeuroGT obtained the Exclusive License Agreement from the Office of Technology Commercialization, University of North Carolina at Chapel Hill (UNC-CH), to develop the gene therapy product NGT-104 for treating Sanfilippo B (MPS IIIB).